Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 120
Filter
2.
Dig Dis Sci ; 66(1): 190-198, 2021 01.
Article in English | MEDLINE | ID: mdl-32144603

ABSTRACT

BACKGROUND: The advent of tumor necrosis factor-α (TNF-α) inhibitor therapy has transformed inflammatory bowel disease management; however, these medications carry a boxed warning for risk of serious infections, including invasive fungal infections. AIMS: We aimed to study the clinical features, severity, and outcomes of histoplasmosis in patients on TNF-α inhibitors for IBD. METHODS: We performed a retrospective review of IBD patients receiving TNF-α inhibitors who developed histoplasmosis from January 1, 2001, to May 31, 2018. Patients with drug indications other than ulcerative colitis or Crohn's disease were excluded. IBD was diagnosed histologically, radiographically, or endoscopically. RESULTS: We identified 49 patients (median age 44 years; range 19-76) with histoplasmosis on TNF-α inhibitors. Patients with disseminated disease had a median urine antigen of 10.76 ng/mL compared with pulmonary disease alone 0.375 ng/mL (p < 0.001). Charlson Comorbidity Index and urine antigen levels showed a trend toward predicting disease severity (p > 0.05). Median length of stay was 9.5 days. Itraconazole was used for maintenance in all patients. Median follow-up was 4.7 years. Total treatment duration ranged from 3 to 15 months. TNF-α inhibitor therapy was continued in nine and resumed in ten patients after completing antifungals. Three deaths occurred (6%). CONCLUSIONS: Histoplasmosis outcomes were mostly favorable. Many patients were young with few comorbidities; however, those with more comorbidities experienced more severe histoplasmosis. Compared to prior studies, many of these patients resumed or continued biologic therapy. There were no histoplasmosis recurrences after resuming TNF-α inhibitor therapy. Vigilance for disseminated fungal infections in this patient population is essential.


Subject(s)
Biological Products/therapeutic use , Histoplasmosis/diagnostic imaging , Histoplasmosis/drug therapy , Inflammatory Bowel Diseases/diagnostic imaging , Inflammatory Bowel Diseases/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Adalimumab/pharmacology , Adalimumab/therapeutic use , Adult , Aged , Biological Products/pharmacology , Cohort Studies , Female , Follow-Up Studies , Histoplasmosis/blood , Humans , Inflammatory Bowel Diseases/blood , Infliximab/pharmacology , Infliximab/therapeutic use , Male , Middle Aged , Retrospective Studies , Young Adult
3.
Indian J Pathol Microbiol ; 63(4): 645-647, 2020.
Article in English | MEDLINE | ID: mdl-33154327

ABSTRACT

Histoplasmosis is an opportunistic systemic infection caused by inhaling spores of a thermal dimorphic fungus Histoplasma capsulatum. Disseminated histoplasmosis is the most common form associated with acquired immune deficiency syndrome (AIDS). However, only a few cases of disseminated histoplasmosis are reported in immuno-competent hosts. Most infections in the immunocompetent hosts are asymptomatic or result in mild pulmonary disease. However the presence of Disseminated Histoplasmosis in immunocompetent host probably results due to prolonged exposure and delayed presentation We report two cases of progressive disseminated histoplasmosis in two immunocompetent patients from non-endemic region in Western Rajasthan, India. Also in both the cases, the first diagnosis was suggested by a peripheral blood smear, which is not a classical biological diagnostic method for fungal infection. Careful examination of Peripheral blood smear along with correct clinical history can aid in early diagnosis of disseminated histoplasmosis even in immunocompetent patients.


Subject(s)
Histoplasmosis/blood , Histoplasmosis/diagnosis , Immunocompetence , Invasive Fungal Infections/diagnosis , Antifungal Agents/therapeutic use , Blood Specimen Collection , Fatal Outcome , Histoplasma/pathogenicity , Histoplasmosis/drug therapy , Humans , India , Invasive Fungal Infections/microbiology , Male , Middle Aged , Tertiary Care Centers
4.
AIDS Res Ther ; 17(1): 52, 2020 08 14.
Article in English | MEDLINE | ID: mdl-32795368

ABSTRACT

BACKGROUND: Hemophagocytic lymphohistiocytosis syndrome (HLS) is an immune-mediated life-threatening disease considered as a medical emergency, with a potentially fatal multisystem inflammatory outcome. We present a patient that developed HLS and was able to be diagnosed efficiently with the help of an academic research institute of immunology. CASE PRESENTATION: A 21 years old male Mexican with human immunodeficiency virus (HIV), late presenter; who developed cytomegalovirus (CMV) infection and a disseminated histoplasmosis-related HLS, as part of an immune reconstitution inflammatory syndrome (IRIS). The patient required a long course of corticotherapy, intravenous immunoglobulin and massive transfusions (more than 10 units in 24 h, and a total of 83 units), besides amphotericin-B and ganciclovir treatment. An academic research institute of immunology aided in the accurate diagnosis of HLS with the implementation of tests not available within the hospital, thus improving the care provided to the patient. The patient recovered, was discharged, and continue to improve. CONCLUSION: The objective of this report is to highlight the importance of having multidisciplinary support, including basic medical sciences groups providing specific tests that are sometimes very difficult to get, which provides a benefit to patients in the well-aimed diagnosis as part of applied translational medicine.


Subject(s)
Cytomegalovirus Infections/diagnosis , Histoplasmosis/blood , Lymphohistiocytosis, Hemophagocytic/diagnosis , Antiviral Agents/therapeutic use , HIV Infections/complications , HIV Infections/virology , Histoplasmosis/complications , Humans , Immunoglobulins, Intravenous/therapeutic use , Lymphohistiocytosis, Hemophagocytic/etiology , Lymphohistiocytosis, Hemophagocytic/therapy , Male , Treatment Outcome , Young Adult
5.
BMJ Case Rep ; 13(6)2020 Jun 11.
Article in English | MEDLINE | ID: mdl-32532906

ABSTRACT

A 50-year-old woman with a history of kidney transplant presented with 2 days of abdominal pain after 6 months of recurrent streptococcal pharyngitis, fevers, weight loss and a new rash on her chest and back. Her examination was notable for a unilateral tonsillar exudate and 2-3 mm pink papules with a fine scale over her chest and back. CT of the abdomen and chest demonstrated several large lymph nodes, and laboratory investigation revealed new cytopenias and elevated transaminases. Urine antigen testing for Histoplasma capsulatum was negative, but a fungal complement fixation panel was reactive for Histoplasma antibodies. Skin biopsy revealed intracellular organisms consistent with H. capsulatum She underwent treatment with liposomal amphotericin B but due to nephrotoxicity, drug interactions and worsening transaminitis, therapy was changed to itraconazole. The diagnosis and management of disseminated histoplasmosis presents multiple challenges, which are of particular importance in patients with a history of renal transplantation.


Subject(s)
Antibodies, Fungal/blood , Histoplasma , Histoplasmosis , Itraconazole/administration & dosage , Kidney Transplantation , Lymphadenopathy , Tomography, X-Ray Computed/methods , Antifungal Agents/administration & dosage , Antigens, Fungal , Diagnosis, Differential , Female , Histoplasma/immunology , Histoplasma/isolation & purification , Histoplasmosis/blood , Histoplasmosis/diagnosis , Histoplasmosis/physiopathology , Histoplasmosis/therapy , Humans , Immunocompromised Host , Kidney Transplantation/adverse effects , Kidney Transplantation/methods , Lymphadenopathy/diagnostic imaging , Lymphadenopathy/etiology , Lymphoproliferative Disorders/diagnosis , Middle Aged , Postoperative Complications/diagnosis , Radiography, Abdominal/methods , Radiography, Thoracic/methods , Treatment Outcome
6.
Indian J Pathol Microbiol ; 63(2): 309-311, 2020.
Article in English | MEDLINE | ID: mdl-32317542

ABSTRACT

Histoplasma capsulatum is an opportunistic dimorphic fungus caused by inhalation of spores present in the soil. It is extremely rare in the northern Himalayan region of India and is usually asymptomatic. It may rarely progress to disseminated histoplasmosis which is usually observed in immunocompromised patients associated with malignancy, acquired immunodeficiency syndrome or diabetes. The present case is being reported because of unusual cutaneous presentation of disseminated histoplasmosis in an immunocompetent patient of non-endemic region. The case also highlights the importance of fine needle aspiration cytology for its precise early diagnosis and avoiding of further complications.


Subject(s)
Histoplasmosis/diagnosis , Lymphohistiocytosis, Hemophagocytic/diagnosis , Phagocytosis , Skin/pathology , Adult , Biopsy, Fine-Needle , Cytological Techniques , Early Diagnosis , Histoplasma/pathogenicity , Histoplasmosis/blood , Histoplasmosis/complications , Humans , Immunocompetence , Lymphohistiocytosis, Hemophagocytic/pathology , Male , Skin/microbiology
7.
Transplant Proc ; 52(4): 1178-1182, 2020 May.
Article in English | MEDLINE | ID: mdl-32340747

ABSTRACT

BACKGROUND: Pneumonia caused by opportunistic fungi is a serious complication in immunocompromised patients. Hypercalcemia has been described in renal transplantation associated with Pneumocystis jirovecii (PJP) or Histoplasma capsulatum (HCP) pneumonia. METHODS: We describe 5 patients who underwent kidney transplant between 2014 and 2019 and developed hypercalcemia before the diagnosis of pulmonary fungal infection: 4 patients with PJP and 1 with HCP. We assessed calcium metabolism and kidney function by total and ionized calcium, phosphorus, intact parathormone (iPTH), 25-OH vitamin D, 1,25(OH)2 vitamin D, and serum creatinine levels. RESULTS: Mean albumin-corrected calcium and ionized calcium were 12.56 mg/dL (range, 10.8-13.8 mg/dL) and 1.57 mmol/L (range, 1.43-1.69 mmol/L). Patients were normocalcemic, at 10.12 mg/dL (range, 9.6-10.5 mg/dL), before diagnosis and resolved hypercalcemia after antifungal treatment, at 8.86 mg/dL (range, 8.0-9.5 mg/dL). All patients had low or normal iPTH values, at 29.1 pg/mL (range, <3-44 pg/mL), with higher PTH levels 3 months before diagnosis and after treatment, at 147.3 pg/mL (range, 28.1-479 pg/mL) and 117.5 pg/mL (range, 18.2-245 pg/mL), respectively. The mean value for 25-OH vitamin D was 30.8 ng/mL (range, 14.6-62.8 ng/mL). This supports a PTH-independent mechanism, and we postulated an extrarenal production of 1,25(OH)2 vitamin D. CONCLUSION: In kidney transplant patients, hypercalcemia independent of PTH and refractory to treatment should alert for the possibility of opportunistic fungal pneumonia.


Subject(s)
Hypercalcemia/etiology , Immunocompromised Host , Kidney Transplantation , Mycoses/immunology , Opportunistic Infections/complications , Pneumonia/immunology , Adult , Female , Histoplasmosis/blood , Histoplasmosis/immunology , Humans , Hypercalcemia/blood , Hypercalcemia/immunology , Male , Middle Aged , Mycoses/blood , Mycoses/complications , Opportunistic Infections/immunology , Opportunistic Infections/microbiology , Pneumonia/complications , Pneumonia/microbiology , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/immunology , Young Adult
8.
Am J Med ; 133(11): e659-e662, 2020 11.
Article in English | MEDLINE | ID: mdl-32320694

ABSTRACT

BACKGROUND: Histoplasmosis is a rare cause of 1, 25-dihydroxy vitamin-D-mediated hypercalcemia. In this study, we report 2 cases of hypercalcemia secondary to histoplasmosis seen at Mayo Clinic, Rochester and a review of cases reported in the literature. METHODS: We conducted a PubMed search using the keywords "hypercalcemia" and "histoplasmosis." Fourteen cases of hypercalcemia secondary to histoplasmosis were reported between 1977 and 2020. We identified an additional 2 patients from our institution. RESULTS: We reviewed a total of 16 cases. The median age at presentation was 58.5 years (interquartile range, 41.5-68.75 years), and 13 of 16 patients (81.2%) were men. Serum parathyroid hormone level was available in 13 of 16 (81.25%) patients, of whom 11 patients (84.6%) had a low level, 1 patient (7.6%) had a normal level, and 1 patient (7.6%) had an elevated level. 1, 25-dihydroxy vitamin D level was reported in 9 of 16 (56.25%) patients. Of these, 5 patients (55.5%) had levels within normal limits, and 4 patients (44.4%) had levels above normal. Serum angiotensin-converting enzyme level was evaluated in 4 of 16 patients (25%), and it was elevated in all 4 (100%) cases. Four patients received corticosteroids before a diagnosis of histoplasmosis was made, which resulted in rapidly progressive disease and death in 2 patients. CONCLUSIONS: In patients with granulomatous disorder and hypercalcemia, it is crucial to rule out infectious etiologies before initiating steroids. Histoplasmosis can cause nonparathyroid hormone-mediated hypercalcemia and, if not suspected, may have catastrophic implications.


Subject(s)
Histoplasmosis/complications , Hypercalcemia/etiology , Adult , Aged , Antifungal Agents/therapeutic use , Bone Density Conservation Agents/therapeutic use , Calcitonin/therapeutic use , Calcitriol/blood , Diphosphonates/therapeutic use , Female , Fluid Therapy , Histoplasmosis/blood , Histoplasmosis/drug therapy , Humans , Hypercalcemia/blood , Hypercalcemia/therapy , Infant , Male , Middle Aged , Parathyroid Hormone/blood , Parathyroid Hormone-Related Protein/blood , Peptidyl-Dipeptidase A/blood , Phosphorus/blood , Vitamin D/analogs & derivatives , Vitamin D/blood , Young Adult
9.
Exp Clin Transplant ; 18(3): 390-391, 2020 06.
Article in English | MEDLINE | ID: mdl-31050612

ABSTRACT

Histoplasmosis is a rare disease in nonendemic areas. We report a case of a 23-year-old male patient who presented with fever of unknown origin, cytopenias, organomegaly, and allograft dysfunction 4 months after renal transplant with father as donor. Bone marrow examination showed intracellular budding yeast cells, which was confirmed as histoplasmosis by culture of bone marrow biopsy sample. The patient was treated with intravenous liposomal amphotericin and responded well.


Subject(s)
Fever of Unknown Origin/microbiology , Histoplasma/isolation & purification , Histoplasmosis/microbiology , Kidney Transplantation/adverse effects , L-Lactate Dehydrogenase/blood , Administration, Intravenous , Amphotericin B/administration & dosage , Antifungal Agents/administration & dosage , Biomarkers/blood , Fever of Unknown Origin/blood , Fever of Unknown Origin/diagnosis , Histoplasma/drug effects , Histoplasmosis/blood , Histoplasmosis/diagnosis , Histoplasmosis/drug therapy , Humans , Male , Predictive Value of Tests , Treatment Outcome , Young Adult
10.
Transpl Infect Dis ; 21(4): e13126, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31169962

ABSTRACT

We report a case of disseminated histoplasmosis in a renal transplant recipient who presented with a nodular pulmonary lesion and elevated serum and bronchoalveolar lavage (BAL) Aspergillus galatomannan. This almost led to an erroneous diagnosis of invasive aspergillosis since the donor respiratory tract was known to be colonized with Aspergillus terreus. However, distinctive intracelluar Histoplasma yeasts on peripheral blood smear led to early diagnosis and appropriate treatment. The cross-reactivity between Aspergillus galactomannan and Histoplasma antigen is discussed further.


Subject(s)
Histoplasmosis/blood , Histoplasmosis/diagnosis , Kidney Transplantation/adverse effects , Mannans/blood , Transplant Recipients , Antifungal Agents/therapeutic use , Aspergillosis/blood , Aspergillus/immunology , Azure Stains , Blood/microbiology , Bronchoalveolar Lavage Fluid/microbiology , Female , Galactose/analogs & derivatives , Histoplasma/immunology , Histoplasma/isolation & purification , Histoplasmosis/drug therapy , Humans , Middle Aged
12.
Pediatr Nephrol ; 34(5): 825-828, 2019 05.
Article in English | MEDLINE | ID: mdl-30570689
13.
Cancer Epidemiol Biomarkers Prev ; 28(2): 321-326, 2019 02.
Article in English | MEDLINE | ID: mdl-30341097

ABSTRACT

BACKGROUND: Granulomas caused by infectious lung diseases present as indeterminate pulmonary nodules (IPNs) on radiography. Newly available serum enzyme immunoassay (EIA) for histoplasmosis has not been studied for the evaluation of IPNs. We investigated serum biomarkers of histoplasmosis antibodies as an indication of benign disease in IPNs from a highly endemic region. METHODS: A total of 152 serum samples from patients presenting with pulmonary nodules ≤30 mm in maximum diameter were analyzed for histoplasmosis antibodies by immunodiffusion and EIA IgG and IgM tests. Serology and FDG-PET/CT scan diagnostic test characteristics were estimated and compared. RESULTS: Cancer prevalence was 55% (n = 83). Thirty-nine (26%) individuals were positive for IgG histoplasmosis antibodies. Twelve samples were IgM antibody positive. Immunodiffusion serology was similar to IgM antibody results with 13 positive tests. Diagnostic likelihood ratios for benign disease were 0.62, 0.33, and 0.28 for FDG-PET/CT, IgG, and IgM antibodies, respectively. When both IgG and IgM were positive (n = 8), no nodules were cancerous and six were FDG-PET/CT avid. CONCLUSIONS: A positive EIA test for both IgM and IgG strongly suggested histoplasmosis etiology and benign granuloma for 12% of benign nodules arising from a highly endemic region. Presence of either IgG or IgM histoplasma antibodies was associated with benign disease. The EIA test was more sensitive in assessing histoplasma exposure than immunodiffusion serology. IMPACT: A new CLIA-certified histoplasmosis antibody EIA test measures histoplasmosis exposure, offers a possible alternative clinical diagnosis for benign IPNs, and may improve IPN evaluation while avoiding harmful invasive biopsies.


Subject(s)
Granuloma/diagnostic imaging , Histoplasmosis/immunology , Immunoenzyme Techniques , Immunoglobulin G/blood , Immunoglobulin M/blood , Lung Diseases, Fungal/immunology , Aged , Female , Histoplasma , Histoplasmosis/blood , Histoplasmosis/complications , Histoplasmosis/diagnostic imaging , Humans , Lung Diseases, Fungal/blood , Lung Diseases, Fungal/complications , Lung Diseases, Fungal/diagnostic imaging , Lung Neoplasms/complications , Male , Middle Aged , Positron-Emission Tomography , Sensitivity and Specificity
14.
Med Mycol ; 57(6): 724-732, 2019 Aug 01.
Article in English | MEDLINE | ID: mdl-30534945

ABSTRACT

Histoplasmosis is the most common endemic mycosis in the Americas. Currently, there is no laboratory test capable to detect subclinical or latent infections by Histoplasma capsulatum (Hc), which might develop as severe infections in immunocompromised individuals. For the first time to our knowledge, we explore the suitability of an interferon gamma release assay (IGRA) to detect latent Hc infection in asymptomatic individuals. A cohort of 126 volunteers was enrolled in the study, 13 of which underwent a Hc infection in the past, and 93 of them showing risk factors for this infection. The remaining 20 participants did not refer any risk factors of Hc infection, but eight of them showed evidences of infection with Mycobacterium tuberculosis. All participants were recruited in Medellin, Colombia, between January 2014 and December 2017. Whole blood samples were cultured with four different Hc crude antigens and phytohemaglutinin as positive control. The interferon (IFN)-γ released by T lymphocytes upon antigen stimulation was quantified by ELISA. A defined cutoff value of 20 pg/ml for the IFN-γ concentration allowed us to distinguish between the group with documented past infections and the group of noninfected individuals with high sensitivity (70-92%) and specificity (85-95%), for the four tested antigens. Positive 82-95% and negative 77-92% predictive values were also very high, comparable to those reported for commercially available IGRAs. The new test constitutes a promising screening method to detect individuals with latent Hc infection, even decades after the primary infection, as evidenced in this study.


Subject(s)
Asymptomatic Infections , Histoplasmosis/diagnosis , Interferon-gamma Release Tests , Adolescent , Adult , Aged , Aged, 80 and over , Antigens, Fungal/immunology , Child , Cohort Studies , Colombia , Female , Histoplasma/isolation & purification , Histoplasmosis/blood , Histoplasmosis/immunology , Humans , Male , Middle Aged , Predictive Value of Tests , Proof of Concept Study , Risk Factors , Sensitivity and Specificity , T-Lymphocytes/immunology , Young Adult
15.
J Mycol Med ; 28(1): 211-214, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29519625

ABSTRACT

Histoplasmosis is a fungal infection caused by a dimorphic fungus, Histoplasma capsulatum. We report a first case of disseminated histoplasmosis in a 34-year-old woman, infected with human immunodeficiency virus (HIV), originating from Ivory Coast and living in Tunisia for 4 years. She was complaining from fever, chronic diarrhoea and pancytopenia. The Histoplasma capsulatum var. capsulatum was identified by direct microscopic examination of the bone marrow. She was treated by Amphotericin B, relayed by itraconazole. Even though a regression of symptoms and normalization of blood cell count (BCC), the patient died in a respiratory distress related to CMV hypoxemic pneumonia.


Subject(s)
Bone Marrow/microbiology , HIV Infections/microbiology , Histoplasma/isolation & purification , Histoplasmosis/blood , Histoplasmosis/diagnosis , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/epidemiology , AIDS-Related Opportunistic Infections/microbiology , AIDS-Related Opportunistic Infections/virology , Adult , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Communicable Diseases, Imported/epidemiology , Communicable Diseases, Imported/microbiology , Cote d'Ivoire/epidemiology , Fatal Outcome , Female , HIV Infections/complications , HIV Infections/epidemiology , Histoplasma/ultrastructure , Histoplasmosis/epidemiology , Histoplasmosis/microbiology , Humans , Itraconazole/therapeutic use , Microscopy , Respiratory Distress Syndrome/epidemiology , Respiratory Distress Syndrome/microbiology , Tunisia/epidemiology
16.
J Gen Intern Med ; 33(5): 769-772, 2018 05.
Article in English | MEDLINE | ID: mdl-29532302

ABSTRACT

Biologic agents are effective treatments for rheumatoid arthritis but are associated with important risks, including severe infections. Tumor Necrosis Factor (TNF) α inhibitors are known to increase the risk of systemic fungal infections such as disseminated histoplasmosis. Abatacept is a biologic agent with a mechanism different from that of TNFα inhibitors: It suppresses cellular immunity by competing for the costimulatory signal on antigen-presenting cells. The risk of disseminated histoplasmosis for patients on abatacept is not known. We report a case of abatacept-associated disseminated histoplasmosis and review the known infectious complications of abatacept. While the safety of resuming biologic agents following treatment for disseminated histoplasmosis is also not known, abatacept is recommended over TNFα inhibitors for rheumatoid arthritis patients with a prior serious infection. We discuss the evidence supporting this recommendation and discuss alternative treatments for rheumatoid arthritis patients with a history of a serious infection.


Subject(s)
Abatacept/adverse effects , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Histoplasmosis/chemically induced , Abatacept/administration & dosage , Antirheumatic Agents/administration & dosage , Female , Histoplasma/cytology , Histoplasma/isolation & purification , Histoplasmosis/blood , Histoplasmosis/diagnosis , Humans , Middle Aged
17.
Am J Clin Pathol ; 149(4): 362-368, 2018 Mar 07.
Article in English | MEDLINE | ID: mdl-29462251

ABSTRACT

OBJECTIVES: Serum and urine antigen (SAg, UAg) detection are common tests for Histoplasma capsulatum. UAg detection is more widely used and reportedly has a higher sensitivity. We investigated whether SAg detection contributes meaningfully to the initial evaluation of patients with suspected histoplasmosis. METHODS: We reviewed 20,285 UAg and 1,426 SAg tests ordered from 1997 to 2016 and analyzed paired UAg and SAg tests completed on the same patient within 1 week. We determined the positivity rate for each test. RESULTS: Of 601 paired specimens, 542 were concurrent negatives and 48 were concurrent positives (98% agreement). Medical records were available for eight of 11 pairs with discrepant results. UAg was falsely positive in six instances, truly positive once, and falsely negative once. CONCLUSIONS: These findings support using a single antigen detection test, rather than both UAg and SAg, as an initial screen for suspected histoplasmosis. This aligns with the current practice of most physicians.


Subject(s)
Antigens, Fungal/urine , Histoplasma/immunology , Histoplasmosis/diagnosis , Adult , Aged , Antigens, Fungal/blood , Biomarkers/blood , Biomarkers/urine , False Negative Reactions , False Positive Reactions , Female , Histoplasma/isolation & purification , Histoplasmosis/blood , Histoplasmosis/urine , Humans , Male , Middle Aged , Retrospective Studies , Sensitivity and Specificity
18.
Braz. j. infect. dis ; 22(1): 11-15, Jan.-feb. 2018. tab, graf
Article in English | LILACS | ID: biblio-951617

ABSTRACT

ABSTRACT Fluconazole is extensively used for the treatment of candidiasis and cryptococcosis. Among other factors, successful treatment is related to appropriate fluconazole levels in blood and cerebrospinal fluid. In the present study, fluconazole levels were determined in 15 patients, 14 of whom had AIDS and 13 had neurocryptococcosis. The only selection criterion was treatment with fluconazole, which was performed with a generic or similar form of the drug. Fluconazole level was determined by high performance liquid chromatography and the susceptibility profile of Cryptococcus spp. isolated from the patients was assessed by broth microdilution. Blood and cerebrospinal fluid fluconazole levels were found to be related to the fluconazole daily dose, and exceeded the minimum inhibitory concentration of this antifungal for the Cryptococcus spp. isolates. A good correlation was observed between serum and cerebrospinal fluid drug concentration. In conclusion, treatment with non-original fluconazole under usual medical practice conditions results in appropriate blood and cerebrospinal fluid levels of the drug for inhibiting Cryptococcus spp. susceptible to this antifungal drug. The relatively common failures of neurocryptococcosis treatment appear not to be due to insufficient fluconazole levels in the cerebrospinal fluid, especially with the use of daily doses of 400-800 mg.


Subject(s)
Humans , Adult , Middle Aged , Fluconazole/cerebrospinal fluid , Fluconazole/blood , Cryptococcosis/drug therapy , Antifungal Agents/cerebrospinal fluid , Antifungal Agents/blood , Reference Values , Candidiasis/cerebrospinal fluid , Candidiasis/drug therapy , Candidiasis/blood , Microbial Sensitivity Tests , Fluconazole/administration & dosage , Chromatography, High Pressure Liquid , Treatment Outcome , AIDS-Related Opportunistic Infections/drug therapy , Statistics, Nonparametric , Cryptococcosis/cerebrospinal fluid , Cryptococcosis/blood , Cryptococcus/isolation & purification , Cryptococcus/drug effects , Dose-Response Relationship, Drug , Histoplasmosis/cerebrospinal fluid , Histoplasmosis/drug therapy , Histoplasmosis/blood , Antifungal Agents/administration & dosage
19.
Braz J Infect Dis ; 22(1): 11-15, 2018.
Article in English | MEDLINE | ID: mdl-29144957

ABSTRACT

Fluconazole is extensively used for the treatment of candidiasis and cryptococcosis. Among other factors, successful treatment is related to appropriate fluconazole levels in blood and cerebrospinal fluid. In the present study, fluconazole levels were determined in 15 patients, 14 of whom had AIDS and 13 had neurocryptococcosis. The only selection criterion was treatment with fluconazole, which was performed with a generic or similar form of the drug. Fluconazole level was determined by high performance liquid chromatography and the susceptibility profile of Cryptococcus spp. isolated from the patients was assessed by broth microdilution. Blood and cerebrospinal fluid fluconazole levels were found to be related to the fluconazole daily dose, and exceeded the minimum inhibitory concentration of this antifungal for the Cryptococcus spp. isolates. A good correlation was observed between serum and cerebrospinal fluid drug concentration. In conclusion, treatment with non-original fluconazole under usual medical practice conditions results in appropriate blood and cerebrospinal fluid levels of the drug for inhibiting Cryptococcus spp. susceptible to this antifungal drug. The relatively common failures of neurocryptococcosis treatment appear not to be due to insufficient fluconazole levels in the cerebrospinal fluid, especially with the use of daily doses of 400-800mg.


Subject(s)
Antifungal Agents/blood , Antifungal Agents/cerebrospinal fluid , Cryptococcosis/drug therapy , Fluconazole/blood , Fluconazole/cerebrospinal fluid , AIDS-Related Opportunistic Infections/drug therapy , Adult , Antifungal Agents/administration & dosage , Candidiasis/blood , Candidiasis/cerebrospinal fluid , Candidiasis/drug therapy , Chromatography, High Pressure Liquid , Cryptococcosis/blood , Cryptococcosis/cerebrospinal fluid , Cryptococcus/drug effects , Cryptococcus/isolation & purification , Dose-Response Relationship, Drug , Fluconazole/administration & dosage , Histoplasmosis/blood , Histoplasmosis/cerebrospinal fluid , Histoplasmosis/drug therapy , Humans , Microbial Sensitivity Tests , Middle Aged , Reference Values , Statistics, Nonparametric , Treatment Outcome
20.
World J Gastroenterol ; 23(43): 7807-7812, 2017 Nov 21.
Article in English | MEDLINE | ID: mdl-29209121

ABSTRACT

We report a case of ileo-colonic Histoplasmosis without apparent respiratory involvement in a patient who had previously undergone an orthotopic liver transplant (OLT) for primary biliary cholangitis 15 years earlier. The recipient lived in the United Kingdom, a non-endemic region for Histoplasmosis. However, she had previously lived in rural southern Africa prior to her OLT. The patient presented with iron deficiency anaemia, diarrhoea, abdominal pain and progressive weight loss. She reported no previous foreign travel, however, it later became known that following her OLT she had been on holiday to rural southern Africa. On investigation, a mild granulomatous colitis primarily affecting the right colon was identified, that initially improved with mesalazine. Her symptoms worsened after 18 mo with progressive ulceration of her distal small bowel and right colon. Mycobacterial, Yersinia, cytomegalovirus and human immunodeficiency virus infections were excluded and the patient was treated with prednisolone for a working diagnosis of Crohn's disease. Despite some early symptom improvement following steroids, there was subsequent deterioration with the patient developing gram-negative sepsis and multi-organ failure, leading to her death. Post-mortem examination revealed that her ileo-colonic inflammation was caused by Histoplasmosis.


Subject(s)
Histoplasma/isolation & purification , Histoplasmosis/diagnosis , Immunosuppressive Agents/adverse effects , Liver Transplantation/adverse effects , Travel-Related Illness , Abdominal Pain/blood , Abdominal Pain/diagnosis , Abdominal Pain/microbiology , Africa, Southern , Aged , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/diagnosis , Anemia, Iron-Deficiency/microbiology , Cholangitis, Sclerosing/surgery , Crohn Disease/diagnosis , Diagnosis, Differential , Diarrhea/blood , Diarrhea/diagnosis , Diarrhea/microbiology , Fatal Outcome , Female , Histoplasmosis/blood , Histoplasmosis/microbiology , Humans , Immunocompromised Host , Intestinal Mucosa/microbiology , Intestinal Mucosa/pathology , Multiple Organ Failure/blood , Multiple Organ Failure/diagnosis , Multiple Organ Failure/microbiology , Time Factors , Weight Loss
SELECTION OF CITATIONS
SEARCH DETAIL
...